Insider Selling: AtriCure (NASDAQ:ATRC) Insider Sells $239,861.60 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Justin Noznesky sold 6,182 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

AtriCure Stock Down 1.8%

Shares of NASDAQ:ATRC traded down $0.74 during trading on Thursday, hitting $40.15. 906,805 shares of the company were exchanged, compared to its average volume of 800,251. The firm’s 50 day moving average price is $30.68 and its 200-day moving average price is $31.30. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $43.18. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18. The stock has a market capitalization of $2.04 billion, a P/E ratio of 191.20 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares during the period. Wellington Management Group LLP raised its holdings in shares of AtriCure by 8.1% in the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after buying an additional 322,818 shares during the last quarter. First Light Asset Management LLC boosted its stake in shares of AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after buying an additional 285,083 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of AtriCure by 8.2% during the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after buying an additional 75,862 shares during the period. Finally, GW&K Investment Management LLC grew its holdings in shares of AtriCure by 10.6% during the fourth quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company’s stock worth $37,665,000 after buying an additional 91,054 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Freedom Capital raised AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. UBS Group decreased their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings upgraded AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday. Finally, Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.